
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of February, 2020

Commission File Number: 001-38452

MEREO BIOPHARMA GROUP PLC

(Translation of registrant's name into English)

**4th Floor, One Cavendish Place,
London, W1G 0QE, United Kingdom**
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Exhibit Index

<u>Exhibit No.</u>	<u>Exhibit</u>
99.1	Notification of Director and other PDMR Dealings dated February 20, 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: February 21, 2020

MEREO BIOPHARMA GROUP PLC

By: /s/ Charles Sermon

Name: Charles Sermon

Title: General Counsel

Mereo BioPharma Group plc

("Mereo" or the "Company")

Notification of Director and other PDMR Dealings

London, February 20, 2020 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, on February 20, 2020 granted incentive awards as set out below to persons discharging managerial responsibilities (PDMRs). All the awards were granted for nil consideration and shall ordinarily be forfeit (to the extent unvested) upon cessation of service.

Options to acquire American Depositary Shares ("ADSs") at an exercise price of \$1.84 per ADS (Fair Market Value at grant) under the Mereo BioPharma Group plc 2019 Equity Incentive Plan (an employees' share scheme):

<u>Name of PDMR</u>	<u>Position</u>	<u>Number of ADSs over which Option granted</u>
Denise Scots-Knight	Chief Executive Officer	175,000
Alastair MacKinnon	Chief Medical Officer	85,000
Richard Jones	Chief Financial Officer	85,000
Charles Sermon	General Counsel	85,000
John Richard	Head of Corporate Development	85,000
Wills Hughes-Wilson	Head of Patient Access and Commercial Planning	50,000

These Options shall normally vest and become exercisable as to one quarter on the first anniversary of their grant date and, thereafter, as to the balance in equal monthly instalments over the three-year period following such anniversary.

Options to acquire ADSs at an exercise price of \$1.84 per ADS (Fair Market Value at grant) under the Mereo BioPharma Group plc 2019 Non-Employee Equity Incentive Plan:

<u>Name of PDMR</u>	<u>Position</u>	<u>Number of ADSs over which Option granted</u>
Peter Fellner	Chairman	11,000
Anders Ekblom	Director	11,000
Peter Bains	Director	11,000
Kunal Kashyap	Director	11,000
Paul Blackburn	Director	11,000
Deepa Pakianathan	Director	11,000
Michael Wyzga	Director	11,000

These Options shall normally vest and become exercisable in equal monthly instalments over the year following their grant date.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The forms required under the EU Market Abuse Regulation follow.

1 Details of the person discharging managerial responsibilities

a) Name Denise Scots-Knight

2 Reason for the notification

- a) Position/status Chief Executive Officer
- b) Initial notification/
Amendment Initial notification
- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name Mereo BioPharma Group plc
- b) LEI 213800U8JQHJIOS5AS09
- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
- a) Description of the financial instrument, type of instrument and identification code AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MERO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH
- b) Nature of the transaction GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MERO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US\$1.84 PER ADS (FAIR MARKET VALUE AT GRANT)
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| NIL | 175,000 |
- d) Aggregated information: volume, Price NOT APPLICABLE - SINGLE TRANSACTION
- e) Date of the transaction February 20, 2020
- f) Place of the transaction Outside of a trading venue
- 1 Details of the person discharging managerial responsibilities
- a) Name Alastair MacKinnon
- 2 Reason for the notification
- a) Position/status Chief Medical Officer
- b) Initial notification/
Amendment Initial notification
- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name Mereo BioPharma Group plc
- b) LEI 213800U8JQHJIOS5AS09
- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
- a) Description of the financial instrument, type of instrument and identification code AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MERO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b) Nature of the transaction	GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MERO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US\$1.84 PER ADS (FAIR MARKET VALUE AT GRANT)	
c) Price(s) and volume(s)	Price(s) NIL	Volume(s) 85,000
d) Aggregated information: volume, Price	NOT APPLICABLE - SINGLE TRANSACTION	
e) Date of the transaction	February 20, 2020	
f) Place of the transaction	Outside of a trading venue	
1 Details of the person discharging managerial responsibilities		
a) Name	Richard Jones	
2 Reason for the notification		
a) Position/status	Chief Financial Officer	
b) Initial notification/ Amendment	Initial notification	
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a) Name	Mereo BioPharma Group plc	
b) LEI	213800U8JQHJOS5AS09	
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a) Description of the financial instrument, type of instrument and identification code	AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MERO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH	
b) Nature of the transaction	GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MERO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US\$1.84 PER ADS (FAIR MARKET VALUE AT GRANT)	
c) Price(s) and volume(s)	Price(s) NIL	Volume(s) 85,000
d) Aggregated information: volume, Price	NOT APPLICABLE - SINGLE TRANSACTION	

- e) Date of the transaction February 20, 2020
- f) Place of the transaction Outside of a trading venue
- 1 Details of the person discharging managerial responsibilities
- a) Name Charles Sermon
- 2 Reason for the notification
- a) Position/status General Counsel
- b) Initial notification/
Amendment Initial notification
- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name Mereo BioPharma Group plc
- b) LEI 213800U8JQHJOS5AS09
- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
- a) Description of the financial instrument, type of instrument and identification code AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH
- b) Nature of the transaction GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US\$1.84 PER ADS (FAIR MARKET VALUE AT GRANT)
- c) Price(s) and volume(s)
- | | |
|----------|-----------|
| Price(s) | Volume(s) |
| NIL | 85,000 |
- d) Aggregated information: volume, Price NOT APPLICABLE - SINGLE TRANSACTION
- e) Date of the transaction February 20, 2020
- f) Place of the transaction Outside of a trading venue
- 1 Details of the person discharging managerial responsibilities
- a) Name Wills Hughes-Wilson
- 2 Reason for the notification
- a) Position/status Head of Patient Access and Commercial Planning

- b) Initial notification/ Amendment Initial notification
- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name Mereo BioPharma Group plc
- b) LEI 213800U8JQHJIOS5AS09
- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
- a) Description of the financial instrument, type of instrument and identification code AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MERO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH
- b) Nature of the transaction GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MERO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US\$1.84 PER ADS (FAIR MARKET VALUE AT GRANT)
- c) Price(s) and volume(s)
- | | |
|----------|-----------|
| Price(s) | Volume(s) |
| NIL | 50,000 |
- d) Aggregated information: volume, Price NOT APPLICABLE - SINGLE TRANSACTION
- e) Date of the transaction February 20, 2020
- f) Place of the transaction Outside of a trading venue
- 1 Details of the person discharging managerial responsibilities
- a) Name John Richard
- 2 Reason for the notification
- a) Position/status Head of Corporate Development
- b) Initial notification/ Amendment Initial notification
- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name Mereo BioPharma Group plc
- b) LEI 213800U8JQHJIOS5AS09
- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
- a) Description of the financial instrument, type of instrument and identification code AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MERO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

- b) Nature of the transaction GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MERO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US\$1.84 PER ADS (FAIR MARKET VALUE AT GRANT)
- c) Price(s) and volume(s) Price(s) NIL Volume(s) 85,000
- d) Aggregated information: volume, Price NOT APPLICABLE - SINGLE TRANSACTION
- e) Date of the transaction February 20, 2020
- f) Place of the transaction Outside of a trading venue
- 1 Details of the person discharging managerial responsibilities
- a) Name Peter Fellner
- 2 Reason for the notification
- a) Position/status Chairman
- b) Initial notification/ Amendment Initial notification
- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name Mereo BioPharma Group plc
- b) LEI 213800U8JQHJOS5AS09
- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
- a) Description of the financial instrument, type of instrument and identification code AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MERO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH
- b) Nature of the transaction GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MERO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US\$1.84 PER ADS (FAIR MARKET VALUE AT GRANT).
- c) Price(s) and volume(s) Price(s) NIL Volume(s) 11,000
- d) Aggregated information: volume, Price NOT APPLICABLE - SINGLE TRANSACTION

- e) Date of the transaction February 20, 2020
- f) Place of the transaction Outside of a trading venue
- 1 Details of the person discharging managerial responsibilities
- a) Name Anders Ekblom
- 2 Reason for the notification
- a) Position/status Director
- b) Initial notification/
Amendment Initial notification
- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name Mereo BioPharma Group plc
- b) LEI 213800U8JQHJOS5AS09
- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
- a) Description of the financial instrument, type of instrument and identification code AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH
- b) Nature of the transaction GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US\$1.84 PER ADS (FAIR MARKET VALUE AT GRANT).
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| NIL | 11,000 |
- d) Aggregated information: volume, Price NOT APPLICABLE - SINGLE TRANSACTION
- e) Date of the transaction February 20, 2020
- f) Place of the transaction Outside of a trading venue
- 1 Details of the person discharging managerial responsibilities
- a) Name Peter Bains
- 2 Reason for the notification
- a) Position/status Director
- b) Initial notification/
Amendment Initial notification

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name Mereo BioPharma Group plc
b) LEI 213800U8JQHJOS5AS09

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

- a) Description of the financial instrument, type of instrument and identification code AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEROO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH
- b) Nature of the transaction GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEROO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US\$1.84 PER ADS (FAIR MARKET VALUE AT GRANT).
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| NIL | 11,000 |
- d) Aggregated information: volume, Price NOT APPLICABLE - SINGLE TRANSACTION
- e) Date of the transaction February 20, 2020
- f) Place of the transaction Outside of a trading venue

1 Details of the person discharging managerial responsibilities

- a) Name Kunal Kashyap

2 Reason for the notification

- a) Position/status Director
b) Initial notification/ Amendment Initial notification

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name Mereo BioPharma Group plc
b) LEI 213800U8JQHJOS5AS09

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

- a) Description of the financial instrument, type of instrument and identification code AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEROO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b) Nature of the transaction	GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MERO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US\$1.84 PER ADS (FAIR MARKET VALUE AT GRANT).	
c) Price(s) and volume(s)	Price(s) NIL	Volume(s) 11,000
d) Aggregated information: volume, Price	NOT APPLICABLE - SINGLE TRANSACTION	
e) Date of the transaction	February 20, 2020	
f) Place of the transaction	Outside of a trading venue	

1 Details of the person discharging managerial responsibilities

a) Name Paul Blackburn

2 Reason for the notification

a) Position/status Director

b) Initial notification/
Amendment Initial notification

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name Mereo BioPharma Group plc

b) LEI 213800U8JQHJOS5AS09

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a) Description of the financial instrument, type of instrument and identification code AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MERO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b) Nature of the transaction GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MERO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US\$1.84 PER ADS (FAIR MARKET VALUE AT GRANT).

c) Price(s) and volume(s) Price(s) Volume(s)
NIL 11,000

d) Aggregated information: volume, Price NOT APPLICABLE - SINGLE TRANSACTION

e) Date of the transaction February 20, 2020

f) Place of the transaction Outside of a trading venue

1 Details of the person discharging managerial responsibilities

a) Name Deepa Pakianathan

2 Reason for the notification

a) Position/status Director

b) Initial notification/
Amendment Initial notification

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name Mereo BioPharma Group plc

b) LEI 213800U8JQHJOS5AS09

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a) Description of the financial instrument, type of instrument and identification code AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b) Nature of the transaction GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US\$1.84 PER ADS (FAIR MARKET VALUE AT GRANT).

c) Price(s) and volume(s)

Price(s)	Volume(s)
NIL	11,000

d) Aggregated information: volume, Price NOT APPLICABLE - SINGLE TRANSACTION

e) Date of the transaction February 20, 2020

f) Place of the transaction Outside of a trading venue

1 Details of the person discharging managerial responsibilities

a) Name Michael Wyzga

2 Reason for the notification

a) Position/status Director

b) Initial notification/
Amendment Initial notification

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name Mereo BioPharma Group plc

b) LEI	213800U8JQHJIOS5AS09	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a) Description of the financial instrument, type of instrument and identification code	AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MERE0 BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH	
b) Nature of the transaction	GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MERE0 BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US\$1.84 PER ADS (FAIR MARKET VALUE AT GRANT).	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	NIL	11,000
d) Aggregated information: volume, Price	NOT APPLICABLE - SINGLE TRANSACTION	
e) Date of the transaction	February 20, 2020	
f) Place of the transaction	Outside of a trading venue	